0001193125-20-174063.txt : 20200619 0001193125-20-174063.hdr.sgml : 20200619 20200619163117 ACCESSION NUMBER: 0001193125-20-174063 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20200616 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders FILED AS OF DATE: 20200619 DATE AS OF CHANGE: 20200619 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Atara Biotherapeutics, Inc. CENTRAL INDEX KEY: 0001604464 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 460920988 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36548 FILM NUMBER: 20976026 BUSINESS ADDRESS: STREET 1: 611 GATEWAY BLVD STREET 2: SUITE 900 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-278-8930 MAIL ADDRESS: STREET 1: 611 GATEWAY BLVD STREET 2: SUITE 900 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 8-K 1 d931131d8k.htm 8-K 8-K
false 0001604464 0001604464 2020-06-16 2020-06-16

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 16, 2020

 

Atara Biotherapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

Delaware

  

001-36548

  

46-0920988

(State or Other Jurisdiction
of Incorporation)

  

(Commission
File Number)

  

(IRS Employer

Identification No.)

611 Gateway Boulevard, Suite 900

South San Francisco, CA

  

94080

(Address of Principal Executive Offices)

  

(Zip Code)

Registrant’s Telephone Number, Including Area Code: (650) 278-8930

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities pursuant to Section 12 (b) of the Act:

Title of Each Class

  

Trading 

Symbol(s)

  

Name of Each Exchange

on Which Registered

Common Stock, par value $0.0001 per share

  

ATRA

  

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

Item 5.07 Submission of Matters to a Vote of Security Holders.

On June 16, 2020, Atara Biotherapeutics, Inc. (the “Company”) held its 2020 annual meeting of stockholders (the “Annual Meeting”). The following is a brief description of each matter voted upon at the Annual Meeting, as well as the number of votes cast for or against each matter and the number of abstentions and broker non-votes with respect to each matter. A more complete description of each matter is described in more detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 22, 2020 (the “Proxy Statement”).

1. Election of Directors

Nominee

 

For

 

Withheld

 

Broker Non-Votes

Pascal Touchon, D.V.M.

 

43,309,203

 

4,398,437

 

7,141,344

Carol Gallagher, Pharm.D.

 

36,658,749

 

11,048,891

 

7,141,344

Each of the two nominees for director was elected to serve until the 2023 annual meeting of stockholders and until their successors are elected.

2. Advisory vote on the compensation of the Company’s named executive officers

For

 

Against

 

Abstain

 

Broker Non-Votes

29,808,000

 

15,489,277

 

2,410,363

 

7,141,344

The stockholders approved, on an advisory basis, the compensation awarded to the Company’s named executive officers, as disclosed in the Proxy Statement.

3. Ratification of Appointment of Independent Registered Public Accounting Firm

For

 

Against

 

Abstentions

54,737,941

 

43,707

 

67,336

The stockholders ratified the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2020.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Atara Biotherapeutics, Inc.

     

By:

 

/s/ Amar Murugan

 

Amar Murugan

 

Senior Vice President, General Counsel

Date: June 19, 2020

EX-101.SCH 2 atra-20200616.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 3 atra-20200616_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 4 atra-20200616_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 5 d931131d8k_htm.xml IDEA: XBRL DOCUMENT 0001604464 2020-06-16 2020-06-16 false 0001604464 8-K 2020-06-16 Atara Biotherapeutics, Inc. DE 001-36548 46-0920988 611 Gateway Boulevard Suite 900 South San Francisco CA 94080 (650) 278-8930 false false false false Common Stock, par value $0.0001 per share ATRA NASDAQ false JSON 6 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d931131d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d931131d8k.htm" ] }, "labelLink": { "local": [ "atra-20200616_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "atra-20200616_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "atra-20200616.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "atra", "nsuri": "http://www.atarabio.com/20200616", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "body", "html" ], "baseRef": "d931131d8k.htm", "contextRef": "duration_2020-06-16_to_2020-06-16", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.atarabio.com//20200616/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "body", "html" ], "baseRef": "d931131d8k.htm", "contextRef": "duration_2020-06-16_to_2020-06-16", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.atarabio.com//20200616/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.atarabio.com//20200616/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.atarabio.com//20200616/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.atarabio.com//20200616/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.atarabio.com//20200616/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.atarabio.com//20200616/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.atarabio.com//20200616/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.atarabio.com//20200616/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.atarabio.com//20200616/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.atarabio.com//20200616/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.atarabio.com//20200616/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.atarabio.com//20200616/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.atarabio.com//20200616/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.atarabio.com//20200616/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.atarabio.com//20200616/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.atarabio.com//20200616/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.atarabio.com//20200616/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.atarabio.com//20200616/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.atarabio.com//20200616/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.atarabio.com//20200616/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.atarabio.com//20200616/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.atarabio.com//20200616/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.atarabio.com//20200616/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } XML 7 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.1 html 1 95 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.atarabio.com//20200616/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d931131d8k.htm atra-20200616.xsd atra-20200616_lab.xml atra-20200616_pre.xml http://xbrl.sec.gov/dei/2019-01-31 true false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end ZIP 9 0001193125-20-174063-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-20-174063-xbrl.zip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report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 R1.htm IDEA: XBRL DOCUMENT v3.20.1
Document and Entity Information
Jun. 16, 2020
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001604464
Document Type 8-K
Document Period End Date Jun. 16, 2020
Entity Registrant Name Atara Biotherapeutics, Inc.
Entity Incorporation State Country Code DE
Entity File Number 001-36548
Entity Tax Identification Number 46-0920988
Entity Address, Address Line One 611 Gateway Boulevard
Entity Address, Address Line Two Suite 900
Entity Address, City or Town South San Francisco
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94080
City Area Code (650)
Local Phone Number 278-8930
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, par value $0.0001 per share
Trading Symbol ATRA
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}